InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,460.48
(
0.00%
)
US TECH 100
19,212.80
(
0.25%
)
Dow Jones
39,118.86
(
0.00%
)
Brent Oil
85.45
(
0.39%
)
Bitcoin
62,807.24
(
0.33%
)
Post# of 252444
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 832
Posts 119956
Boards Moderated 17
Alias Born 09/05/2002

DewDiligence

Member Level

Re: genisi post# 123628

Wednesday, 07/20/2011 8:02:20 AM

Wednesday, July 20, 2011 8:02:20 AM

Post# of 252444
In other words, Neugranin does not infringe on AMGN’s Neulasta patents, but it does infringe on AMGN’s Neupogen patents; thus, it makes sense that the AMGN-Teva settlement calls for Neugranin to be launched when the Neupogen patents expire in Nov 2013.

Do you agree with the inference in the bottom paragraph of #msg-65308970, i.e. that the Neulasta knockoff from Ratiopharm will not be brought to market in the US?

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up